Welcome to our dedicated page for Kronos Bio news (Ticker: KRON), a resource for investors and traders seeking the latest updates and insights on Kronos Bio stock.
Kronos Bio Inc. news covers the company's historical work as a biopharmaceutical developer of small molecule therapeutics targeting deregulated transcription in cancer and autoimmune disease. Recurring updates include financial results, strategic-alternative reviews, governance changes, expense reductions, and pipeline decisions involving istisociclib and p300 lysine acetyltransferase inhibitor programs.
Company announcements also describe preclinical research for KB-9558 in multiple myeloma and HPV-driven tumors and KB-7898 in autoimmune indications such as Sjögren's disease. Later corporate updates center on material agreements, shareholder matters, capital-structure disclosure, and public-company status changes following the strategic-review process.
Kronos Bio, Inc. (Nasdaq: KRON) announced participation in two upcoming investor conferences. On Dec. 2, 2020, at 2:15 p.m. ET, management will engage in a virtual fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference. Additionally, on Dec. 3, 2020, meetings will take place at the Piper Sandler 32nd Annual Virtual Healthcare Conference, featuring a pre-recorded fireside chat available from 10 a.m. ET. The events will be accessible via the company’s website, with replays available for one month.
Kronos Bio, Inc. reported significant advancements in its business on November 18, 2020, including the acquisition of SYK inhibitors from Gilead Sciences and plans for late-stage clinical testing of its lead therapy, entospletinib, for NPM1-mutated acute myeloid leukemia. The company raised $287.5 million from its upsized IPO on October 14, 2020, strengthening its financial position. Despite a net loss of $39.7 million for Q3 2020, Kronos is well-capitalized for ongoing research and development, showing promising growth potential.
Kronos Bio, Inc. (Nasdaq: KRON) announced participation in a fireside chat at the Jefferies Virtual London Healthcare Conference on Nov. 18, 2020, at 7:20 p.m. GMT (2:20 p.m. ET). The event will be streamed live via the company's website, with a replay available for one month after. Kronos Bio focuses on developing therapies for cancer, particularly through targeting dysregulated transcription factors. Their lead investigational therapy, entospletinib, targets spleen tyrosine kinase (SYK) for NPM1-mutated acute myeloid leukemia (AML), and they are also working on KB-0742 for MYC-amplified solid tumors.
Kronos Bio announced promising results for its investigational therapy, KB-0742, targeting castration-resistant prostate cancer (CRPC). In preclinical studies, KB-0742 demonstrated an 82% tumor growth inhibition compared to 70% with standard chemotherapy. This selective CDK9 inhibitor effectively reduced AR-driven transcriptional activity and promoted apoptosis in CRPC cell lines. The company plans to submit an IND by Q4 2020 and initiate a Phase 1/2 clinical trial in 2021. These advancements position KB-0742 as a potential treatment for high MYC-amplification tumors, addressing a significant unmet medical need.
Kronos Bio, Inc. (Nasdaq: KRON) has successfully closed its initial public offering, selling 15,131,579 shares at $19.00 each, including 1,973,684 shares sold through underwriters' option. This offering generated approximately $287.5 million in gross proceeds. The shares commenced trading on Nasdaq on October 9, 2020. Goldman Sachs, Jefferies, Cowen, and Piper Sandler acted as joint book-running managers. The registration statement for these securities was effective as of October 8, 2020.
Kronos Bio, a clinical-stage biopharmaceutical company, has priced its initial public offering (IPO) of 13,157,895 shares at $19.00 per share, aiming to raise approximately $250 million before expenses. The shares are set to trade on the Nasdaq Global Select Market under the symbol 'KRON' starting October 9, 2020, with the offering expected to close on October 14, 2020. The company has granted underwriters a 30-day option to purchase an additional 1,973,684 shares. Goldman Sachs, Jefferies, Cowen, and Piper Sandler are leading the offering.